Candel soars on prostate cancer data despite unclear prospects
Candel Therapeutics’ viral immunotherapy candidate passed a late-stage test in certain patients with prostate cancer, sending its share price {$CADL} up around 60% even as the same treatment flunked a...
View ArticleNIH halts enrollment in trial for SIGA's mpox antiviral after disappointing data
Another trial for SIGA Technologies' mpox antiviral has failed, and all enrollment has been stopped, the NIH's National Institute of Allergy and Infectious Diseases announced this week. SIGA’s...
View ArticleDrugs are approved and available faster in US than most of EU, data show
New drugs in the US were, on average, approved months before winning approval in the EU, according to new data from The IQVIA Institute for Human Data Science. The difference can be attributed in part ...
View ArticleRFK Jr. lobbied against vaccine EUAs. At HHS, he could undo them
Robert F. Kennedy Jr., President-elect Donald Trump's choice to lead the Department of Health and Human Services, would have the ability to quickly act on his efforts two years ago to halt use of Covid...
View ArticleLilly to study obesity drugs in addiction, and is considering cognitive...
With supply shortages fading and new indications growing, the main question for obesity drugmakers entering the new year is what they'll try and treat next with the drugs. For Eli Lilly, one answer is...
View ArticleLonza looks to depart capsule and health ingredients as it undergoes restructure
Only six months into the role, Lonza’s new CEO Wolfgang Wienand is already looking to make his mark. Lonza said Thursday it is planning to exit the capsules and health ingredients market as the Swiss ...
View ArticleCorcept’s ALS drug fails to improve function in Phase 2 study
It’s been a tough few months for Corcept Therapeutics. In October, the company’s lead pipeline candidate missed the primary endpoint in a Phase 3 Cushing’s syndrome trial. Now, its only neurology asset...
View ArticleHealthcare veteran Glen Tullman thinks AI implementation will define health...
While there’s already plenty of AI in healthcare that focuses on administrative tasks on the back end, it’s time for AI in health consumer-facing products to shine in the year ahead, Glen Tullman told...
View ArticlePleno raises $25M for multiomics testing, names new CEO
Pleno has raised an additional $25 million in private funding to advance its tests that detect biological targets for drug research and diagnostics. The company uses what it calls hypercoding, which...
View ArticleKeros halts parts of Phase 2 PAH trial due to safety, stock tanks 70%
Keros Therapeutics said Thursday morning it has voluntarily halted two of three dosing arms of its experimental drug in a Phase 2 trial due to a safety concern. The Boston-area biotech said there was...
View ArticlePfizer shares positive Phase 3 results in breast cancer subset
Pfizer touts Ibrance’s status as a standard of care in HR-positive, HER2-negative metastatic breast cancer. Now the company wants to expand to double-positive patients. On Thursday, the drugmaker...
View ArticleIsomorphic Labs CEO Demis Hassabis bets on biotech's AI future
LONDON — Demis Hassabis has no interest in a laboratory. The Nobel Prize-winning artificial intelligence pioneer is betting big on AI’s future in drug discovery. But he’s also grown exasperated at...
View ArticleEli Lilly and Ro’s unlikely relationship
Over the summer, we speculated that the cold war between drugmakers Eli Lilly and Novo Nordisk and the many businesses profiting from copycat versions of their obesity medications would come ...
View ArticleDaiichi's $150M build in China; BioMarin reveals €60M Irish expansion
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Daiichi Sankyo is investing RMB 1.1 billion ...
View ArticleElevation to pay up to $368M in ADC deal; Bavarian Nordic closes San Diego site
Plus, news about Essential Pharma, ADC Therapeutics, Caliway Biopharmaceuticals, AnaptysBio, Andera Partners and NewAmsterdam Pharma: Elevation’s ADC deal: The biotech will pay up to $368 million in...
View ArticlePadlock shareholders sue Bristol Myers over milestone dispute after 2016...
Former shareholders in autoimmune biotech acquired by Bristol Myers Squibb are suing the large pharma for what they claim are missed milestone payments and maneuvers to discredit the biotech’s work. BMS
View Article'Unsupported' drug price increases add to US costs, ICER claims
The Institute for Clinical and Economic Review on Thursday released a new report arguing that US healthcare costs rose by more than $800 million from price increases on just five drugs' net prices,...
View Article'Serious liver injury' cases on Ocaliva lead FDA to call for monitoring
The FDA said it continues to monitor the safety of Intercept Pharmaceuticals and Alfasigma’s rare liver disease drug Ocaliva after seeing evidence of “serious liver injury” in a post-approval clinical...
View ArticleFDA adcomm reviews safety signals from pediatric RSV trials
Advisors to the FDA had difficulty dissecting a small but concerning set of safety data from Moderna’s pediatric RSV vaccine data, largely concluding that other trials should continue to better inform...
View Article